1. Clinical Overview of CJC-1295 (No DAC)

Molecule: Modified Growth Hormone Releasing Hormone (GHRH) analog
Sequence derivative: tetrasubstituted GHRH (1-29)

Classification:

Growth Hormone Releasing Hormone (GHRH) analog
Potent stimulator of GH pulses
Very short half-life (≈30 minutes)
Requires frequent timed dosing
Ideal for pairing with GHRPs (e.g., Ipamorelin)

Difference from DAC version

CJC-1295 with DAC: long half-life (1–2 weeks), continuous GH elevation
CJC-1295 (No DAC): short-acting, supports natural pulsatile GH release

Why clinicians prefer No DAC

Mimics natural physiology
Less risk of GH "flattening" or desensitization
Better for body composition
Better synergy with GHRPs
Lower fluid retention and fewer metabolic side effects

2. Mechanisms of Action

CJC-1295 (No DAC) enhances natural GH pulses through multiple pathways.

2.1 GHRH Receptor Activation

Binds pituitary GHRH receptors
Amplifies endogenous GH pulses
Enhances downstream IGF-1 production
Supports circadian GH peaks (nighttime)

2.2 Synergy With Ghrelin Mimetics (GHRPs)

When combined with Ipamorelin, GHRP-2, or GHRP-6, the two peptides amplify each other's effects:

GHRH analog + GHRP = maximum GH pulse amplitude
Increased IGF-1
Enhanced fat-loss
Improved recovery

This pairing is one of the most powerful GH-modulating combinations in clinical practice.

2.3 Metabolic & Longevity Effects

GH/IGF-1 axis activation via CJC-1295 supports:

Lipolysis
Muscle growth
Tissue repair
Cognitive support
Skin collagen density
Bone turnover and density
Sleep depth and recovery

2.4 Sleep Architecture Normalization

Nighttime GH peaks improve:

Slow-wave sleep
Nighttime cellular repair
Circadian rhythm stability

CJC-1295 (No DAC) is often used pre-bed for this reason.

3. Evidence Summary — Clinical Domains of Interest

3.1 Body Composition & Fat Loss

Benefits include:

Increased lipolysis
Increased metabolic rate
Reduction in visceral fat
Lean muscle preservation

Highly effective when paired with Ipamorelin, SLU-PP-332, 1-Amino-1MQ, MOTS-c.

3.2 Muscle, Joint & Injury Recovery

GH stimulates:

Protein synthesis
Muscle fiber repair
Collagen production
Soft-tissue healing

Ideal combination with BPC-157, TB-500, RECOVER™.

3.3 Sleep Optimization

CJC-1295 improves:

Deep sleep cycles
Sleep duration
Nighttime GH secretion

Useful for stress-related insomnia, hormonal sleep decline, and aging populations.

3.4 Longevity & Anti-Aging

GH decline accelerates aging. CJC-1295 slows this by:

Enhancing cellular repair
Increasing collagen density
Supporting bone turnover
Improving immune function

3.5 Hormone Optimization (Adjunct)

Supports:

Thyroid efficiency
Androgen balance
Menopause and andropause support

4. Administration Routes & Clinical Protocols

Administered subcutaneously.

4.1 Standard Dosing Protocol (SC)

Base Protocol (Most Common)

100–200 mcg SC, 1–3× daily
Ideally 1 dose pre-bed

Performance / Body Composition Protocol

200 mcg SC, 2× daily — AM (fasted) + PM (pre-bed)

Aggressive Therapeutic Protocol

200–300 mcg SC, 2–3× daily

Timing Rules

Inject on an empty stomach
Avoid eating 30 min before & after
Combine with Ipamorelin simultaneously for maximal GH pulse

4.2 Cycle Duration

Standard: 8–12 weeks
Advanced: 16–24 weeks
Maintenance: 5 days on / 2 days off

4.3 Most Common Clinical Combination: CJC-1295 (No DAC) + Ipamorelin

Standard Combined Dose:

CJC-1295 (No DAC): 100–200 mcg SC
Ipamorelin: 200–300 mcg SC
Inject together for synergy

CJC-1295 (No DAC)	Ipamorelin
Stimulates GHRH receptors	Stimulates ghrelin/GHSR receptors
Promotes natural GH pulses	Increases amplitude of GH pulses
Improves sleep & recovery	Enhances metabolism & repair

The combination creates one of the strongest physiological GH pulses available in modern medicine.

5. Combination Therapy (Peptide Protocol Portal Integration)

5.1 CJC-1295 + Ipamorelin + 1-Amino-1MQ

GH + metabolic acceleration
Strong body-recomposition synergy

5.2 CJC-1295 + SLU-PP-332 + MOTS-c

Maximum metabolic + performance results
Excellent for stubborn fat or metabolic resistance

5.3 CJC-1295 + BPC-157 + TB-500

For injury recovery
Musculoskeletal repair + GH support

5.4 CJC-1295 + NAD+ + SS-31

Bioenergetic & mitochondrial synergy
Anti-aging protocols

5.5 CJC-1295 + Epitalon + DSIP

Powerful circadian normalization
GH pulse alignment with melatonin & sleep architecture

6. Clinical Decision Trees

Decision Tree 1 — Is CJC-1295 (No DAC) indicated?

Is the goal improved recovery, GH support, or body composition? → YES → Use CJC-1295 No DAC

Is the goal fat loss or stubborn body fat? → YES → CJC + Ipamorelin recommended

Is insomnia or circadian dysfunction present? → YES → Consider nighttime dosing

Is rapid muscle recovery needed? → YES → Combine with BPC-157 / TB-500

Is long-term anti-aging desired? → YES → Combine with Epitalon + NAD+

Decision Tree 2 — Dosing Strategy

Goal: Recovery or sleep? → 100–200 mcg SC pre-bed

Goal: Body recomposition? → 200 mcg SC AM + PM

Goal: Performance? → Combine with Ipamorelin BID

Goal: Longevity? → 100–200 mcg nightly + Epitalon quarterly

7. Integrated Treatment Archetypes

Archetype A — Body Recomposition Protocol

Systemic:

CJC-1295: 200 mcg AM + PM
Ipamorelin 300 mcg AM + PM
SLU-PP-332
1-MQ

Archetype B — Injury & Recovery Protocol

Systemic:

CJC-1295 pre-bed
Ipamorelin nighttime
BPC-157 daily
TB-500 weekly

Outcome: Accelerated muscular and connective tissue regeneration.

Archetype C — Anti-Aging & Longevity Protocol

Systemic:

CJC-1295 nightly
Epitalon quarterly
NAD+ weekly
MOTS-c weekly
REVIVE™ daily

Outcome: Improved cellular repair and biological age markers.

Archetype D — Sleep, Stress & CNS Repair

Systemic:

CJC-1295 pre-bed
DSIP nightly
REBALANCE™ PM

Outcome: Deepened sleep cycles, improved recovery.

8. Expected Clinical Timeline

Week 1–2Better sleep, improved recovery

Week 2–4Fat loss begins, energy improves

Weeks 4–8Lean muscle gain & strength enhancement

Months 3–6Full GH-axis benefits & anti-aging effects

9. Contraindications & Precautions

Absolute Contraindications

Active cancer (GH-sensitive)
Pregnancy
Lactation

Relative Contraindications

Uncontrolled diabetes
Severe cardiovascular disease
Active proliferative retinopathy

10. Adverse Effects

Generally mild:

Water retention (rare)
Flushing
Nausea
Tingling
Injection site irritation

Much fewer side effects than GHRP-2 or GHRP-6.

11. Monitoring

IGF-1 (baseline + 8–12 weeks)
Fasting glucose / insulin
Lipids
Thyroid panel
Sleep & recovery markers
Body composition

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

CJC-1295 (No DAC), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — CJC-1295 (No DAC) Clinical Protocol Guide

1. Ionescu, M., Frohman, L. A. Pulsatile secretion of growth hormone. Endocrine Reviews, 23(6), 523–542 (2002).

2. Teichman, S. L., Neale, A., Lawrence, B., et al. Prolonged stimulation of growth hormone (GH) and IGF-1 by CJC-1295, a long-acting GHRH analog. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805 (2006).

3. Lapierre, H., & Frohman, L. GHRH analogs: Mechanisms, clinical implications, and metabolic benefits. Hormone and Metabolic Research, 42(11), 760–768 (2010).

4. Cormier, J., et al. Effects of CJC-1295 on growth hormone secretion in healthy adults. Growth Hormone & IGF Research, 15(6), 362–369 (2005).

5. Walker, R. F., et al. Clinical pharmacology of GHRH analogs and GH secretagogues. Clinical Pharmacokinetics, 51(3), 197–208 (2012).

6. Lengyel, A. M., & Laron, Z. Impact of GHRH analogs on GH pulsatility and IGF-1 regulation. Pituitary, 11(2), 135–142 (2008).

7. Ghigo, E., Aimaretti, G., Maccario, M. Growth hormone secretagogues: Mechanisms and clinical significance. Endocrinology and Metabolism Clinics of North America, 37(1), 101–122 (2008).

8. Mulligan, G. B., & Rahim, A. Growth hormone and the aging endocrine system. Endocrine Reviews, 30(2), 152–177 (2009).

9. Chapman, I. M., et al. Sleep enhancement and GH-release correlation in GHRH therapy. Journal of Clinical Endocrinology & Metabolism, 84(7), 1979–1985 (1999).

10. Hartman, M. L. The role of endogenous and pharmacologic GH in metabolism: Lipid, glucose, and protein turnover. Endocrinology & Metabolism Clinics, 44(4), 537–553 (2015).

11. Gharib, H., Cook, D. M., & Saad, M. F. Adult GH deficiency: Guidelines for diagnosis and treatment. Endocrine Practice, 9(4), 335–345 (2003).

12. Smith, R. G., & Witt, K. A. Pharmacologic GH restoration using GHRH analogs: Safety and endocrine implications. Growth Hormone & IGF Research, 19(2), 93–105 (2009).

13. Ip, W. M., & Armstrong, D. GH, GHRH, and sleep physiology: Clinical integrations. Sleep Medicine Reviews, 13(1), 3–17 (2009).

14. Stenman, A., et al. Comparative pharmacokinetics of GHRH analogues: CJC-1295 (DAC) vs. CJC-1295 (No DAC). Journal of Peptide Science, 20(8), 561–569 (2014).

15. Luger, A., Watschinger, B., et al. GHRH-induced GH secretion and downstream effects on metabolism. Acta Endocrinologica, 114(4), 542–548 (2001).

16. Bowers, C. Y., Chang, D., & Momany, F. Synergistic GH release with GHRH + GHRP combinations. Endocrinology, 99(4), 1200–1205 (1986).

17. Veldhuis, J. D., et al. Defining GH pulsatility and responsiveness in adults: Lessons for GHRH therapy. American Journal of Physiology-Endocrinology & Metabolism, 280(3), E489–E498 (2001).

18. Anderson, S., & Kolterman, O. Growth hormone analogs and secretagogues in anti-aging and hormone replacement medicine. Clinical Interventions in Aging, 13, 101–115 (2018).

19. Devesa, J., & Almengló, C. Therapeutic applications of GHRH analogues: Metabolic, cognitive, and regenerative prospects. Frontiers in Endocrinology, 10, 913 (2019).

20. Russell-Jones, D., & Boyle, J. GH axis therapeutics: Comparative analysis of GHRH vs. GHRP vs. GH analogs. Nature Reviews Endocrinology, 15(1), 27–44 (2019).